these evidence support a therapeutic approach based on the selection of a molecular target in a shared area of the inflammatory cascade located upstream in the T2 immunologic pathway. The European ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...

Objective: This study analyzes the occurrence and characteristics of adverse drug reactions (ADRs) of dupilumab in children in a real-world setting. It aims to enhance clinical practice and minimize ...

This study investigates the potential clinical synergy between the PARP inhibitor niraparib (Zejula) and concomitant statins, exploring their combined effects on progression-free survival (PFS) in ...

EADV 2024 Late Dupilumab Responders Have Unique Molecular Profile In a major potential step toward personalized therapy for atopic dermatitis, data suggest early, late, and no clinical response to ...